The Asia Pacific Patient-controlled Analgesic Pumps Market would witness market growth of 11% CAGR during the forecast period (2021-2027).
There are various painful conditions in which patient-controlled analgesic pumps are proved to be effective and they are mainly beneficial in acute postoperative pain management. Unique patient-controlled analgesic treatment like PCRA, PCEA, and noninvasive methods of PCA has increased the alternatives for pain-relief treatment. Along with this, the adoption of these methods would be fueled in the next few years due to the developments in PCA technology such as variable-rate infusions that are evaluated on the basis of patient requirements for analgesia and better patient monitoring.
The growth of the market would be supplemented by the integration of the latest technologies in PCA pumps that assists in the quick pain recovery and hence, encourage patients to opt for this device. For example, Acromed Chroma infusion pumps incorporate the new technology in pain management that enables patients to deliver bolus analgesic medicine themselves. This empowers patients to get relief from the pain and enables them to feel comfortable while reducing the requirement for on-site support from hospital members.
The China market dominated the Asia Pacific Specialty Clinics Market by Country in 2020, thereby, achieving a market value of $10,754.7 Thousands by 2027, growing at a CAGR of 8.2% during the forecast period. The Japan market is exhibiting a CAGR of 11.5% during (2021 - 2027). Additionally, The India market is anticipated to witness a prominent CAGR during (2021 - 2027).
Based on Type, the market is segmented into Electronic and Mechanical. Based on Application, the market is segmented into Oncology, Diabetes, Hematology, Gastroenterology and Others. Based on End-use, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Smiths Group PLC, Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Baxter International, Inc., Becton, Dickinson and Company, Terumo Corporation, Abbott Laboratories, Avante Health Solutions, ICU Medical, Inc., and Ace Medical Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By End Use
• Specialty Clinics
• Ambulatory Surgical Centers
• South Korea
• Rest of Asia Pacific
• Smiths Group PLC
• Fresenius SE & Co. KGaA
• B. Braun Melsungen AG
• Baxter International, Inc.
• Becton, Dickinson and Company
• Terumo Corporation
• Abbott Laboratories
• Avante Health Solutions
• ICU Medical, Inc.
• Ace Medical Co., Ltd.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
Executive Summary The Global Plasma Protein Therapeutics Market is estimated at USD 25.4 billion in the year 2020. New plasma-derived therapies is the primary driving factor for the global plasma protein therapeutics market. Increasing introduction of new plasma-derived therapies with increasing use of Plasma Protein...
The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend...
Executive Summary Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn...
630 pages •
By Roots Analysis Private Ltd.
• Aug 2021
INTRODUCTION Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including...
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4billion in 2021, at a CAGR of 31.4%. Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in...
The global wearable injectors market is projected to reach USD 11.5billion by 2026 from USD 7.2billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various...
The anaphylaxis treatment market in Asia Pacific is expected to grow from US$ 350.7 million in 2021 to US$ 664.0 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028. Novel drug delivery systems support improved drug potency and controlled drug release, along with imparting a sustained therapeutic effect for...
The anaphylaxis treatment market is expected to reach US$ 4,787.66 million in 2028 from US$ 2,664.66 million in 2021; it is estimated to grow at a CAGR of 8.7% during 2021–2028. The growth of the market is mainly attributed to the key driving factors such as the rising incidence of anaphylaxis, and recent approvals of epinephrine. However,...
342 pages •
By Roots Analysis Private Ltd.
• Jun 2021
INTRODUCTION Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as one of the fastest growing classes of pharmacologically active molecules. Till date, over 67% of biologics and 80% of biosimilars approved by the FDA, feature some form of glycosylation. In fact, the pipeline...
Number Of Enterprises
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.